Feasibility of screening for atrial fibrillation in primary care: Just a heartbeat away?
We read with interest the commentary on the implementation of screening for atrial fibrillation (AF) in primary care by Taggar and Coleman. 1 The authors correctly point out that the identification of AF through screening could prevent a substantial number of strokes. However, in terms of screening techniques, the authors note that the specificity of pulse palpation is suboptimal and that techniques such as single-lead electrocardiograph (ECG) may be more accurate.
We also agree that feasibility work is crucial in terms of successfully implementing primary care screening for AF. As two members of our research group pointed out in a recent editorial, 2 the results of any research into feasibility are likely to be largely determined by the relevant setting, health system and culture.
However, Taggar and Coleman state that ''there have been no studies that have investigated the feasibility of introducing [ECG] screening within a primary care setting or the opinions of primary care professionals about screening activities.'' While there may not be have been any such studies conducted in the UK, there has been some work done in this area in Australia and in Europe.
In Europe, Tieleman et al. 3 concluded that it was feasible to screen patients in a primary care setting using a single-lead ECG (the MyDiagnostick) during influenza vaccination. In particular, the authors concluded that the high sensitivity and ease of use of the device would enable large-scale screening for AF.
In 2014, our group published the results of a qualitative pilot study using a single-lead smartphone ECG (iECG) in order to screen for AF in primary care in Australia. 4 We conducted a detailed process evaluation, interviewing patients, receptionists, practice nurses and general practitioners (GPs). Our analysis explored relevant barriers and enablers for each group, and we concluded that screening for AF in primary care using an iECG is feasible. We found that GPs really liked the iECG device and found it to be a valuable tool, and that practice nurses were well placed to explain and conduct such screening.
In 2015, we conducted a pilot study of iECG screening by practice nurses during influenza vaccination. The qualitative results, which were recently presented, 5 explored the barriers and enablers to implementing screening as identified by GPs, practice nurses and practice managers. While many of the barriers were very practice specific (and, indeed, specific to each country's health system), addressing the identified barriers (e.g. funding for screening) is likely to increase uptake. We are continuing this work, and will shortly publish the quantitative results of our 2015 study, as well as a protocol describing our forthcoming study.
We agree that research examining the factors that increase health professional ''enthusiasm'' for performing screening is important and suggest that future research is also required in order assess the scalability and sustainability of successful pilot programmes.
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